GME
72
4
PVH
59
-3
ESS
51
3
IVZ
50
2
BK
65
2
KR
52
2
NWSA
71
-4
PRU
50
3
KSS
42
3
MS
72
2
OMC
39
2
PLD
45
5
TROW
50
2
FDX
40
4
EW
57
2
AAP
32
2
PNR
62
2
NRG
37
-2
LNC
32
3
BAX
41
2
GME
72
4
PVH
59
-3
ESS
51
3
IVZ
50
2
BK
65
2
KR
52
2
NWSA
71
-4
PRU
50
3
KSS
42
3
MS
72
2
OMC
39
2
PLD
45
5
TROW
50
2
FDX
40
4
EW
57
2
AAP
32
2
PNR
62
2
NRG
37
-2
LNC
32
3
BAX
41
2
Financhill
Back

Verrica Pharmaceuticals 10K Form

Sell
32

VRCA
Verrica Pharmaceuticals

Last Price:
$0.65
Seasonality Move:
24.89%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

2020-08-05 10Q VRCA/Verrica Pharmaceuticals Quarterly
2020-05-07 10Q VRCA/Verrica Pharmaceuticals Quarterly
2020-03-13 10K VRCA/Verrica Pharmaceuticals Annual
2019-11-06 10Q VRCA/Verrica Pharmaceuticals Quarterly
2019-08-07 10Q VRCA/Verrica Pharmaceuticals Quarterly
2019-05-07 10Q VRCA/Verrica Pharmaceuticals Quarterly

Receive VRCA News And Ratings

See the #1 stock for the next 7 days that we like better than VRCA

VRCA Financial Statistics

Sales & Book Value

Annual Sales: $5.1M
Cash Flow: $-8.6M
Price / Cash Flow: 0
Annual Sales: $-0.75
Price / Book: 196.35

Profitability

EPS (TTM): -1.84000
Net Income (TTM): $-85M
Gross Margin: $4.4M
Return on Equity: -2619.46%
Return on Assets: -128.78%

Verrica Pharmaceuticals Earnings Forecast

Key Verrica Pharmaceuticals Financial Ratios

  • The Gross Profit Margin over the past 3 years for VRCA is 85.44%.
  • The Selling, General & Administrative Expenses for VRCA have been equal to 923.20% of Gross Profit Margin.
  • The Research & Development expenses have been 396.08% of Revenue.
  • The Interest Expense is -5.91% of Operating Income.
  • The Net Earning history of VRCA is -1,307.47% of Total Revenues.
  • Per Share Earnings over the last 8 years have been positive in 3 years.

Verrica Pharmaceuticals Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceuticals
Sector: Health Care
Current Symbol: VRCA
CUSIP: 92511W
Website: verrica.com

Debt

Debt-to-Equity Ratio: -1.27
Current Ratio: 1.34
Quick Ratio: 1.1

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

VRCA Technical Analysis vs Fundamental Analysis

Sell
32
Verrica Pharmaceuticals (VRCA) is a Sell

Is Verrica Pharmaceuticals a Buy or a Sell?